In yet another twist to the ongoing debate over the Oxford/AstraZeneca PLC COVID-19 vaccine, the Swiss regulatory agency has said that the data the company has submitted so far “are not yet sufficient to permit authorization.”
In other COVID vaccine-related news, the European Medicines Agency has announced that its human medicines committee, the CHMP, has started a rolling review of NVX-CoV2373, a COVID‑19 vaccine being developed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?